Are you Dr. Leese?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 37 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6700 W 115th St
Overland Park, KS 66211Phone+1 913-708-7555Fax+1 913-708-7607- Is this information wrong?
Summary
- Dr. Philip Leese, MD is an internist in Overland Park, Kansas. He is currently licensed to practice medicine in Kansas and Missouri.
Education & Training
- Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 1976 - 1979
- Creighton University School of MedicineClass of 1976
Certifications & Licensure
- KS State Medical License 1980 - 2022
- MO State Medical License 1979 - 2014
Clinical Trials
- A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine Start of enrollment: 2006 Sep 01
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers Start of enrollment: 2006 Nov 01
- A/H5N1 Dose Ranging Study With Adjuvant Patch Start of enrollment: 2007 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsEffects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical StudiesPaul D. Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Dominic Surry, David J. Sweeny, David Lau, Philip T. Leese> ;Clinical Pharmacology in Drug Development. 2016 May 1
- 99 citationsOsimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinica...David Planchard, Kathryn H. Brown, Dong Wan Kim, Sang-We Kim, Yuichiro Ohe, Enriqueta Felip, Philip T. Leese, Mireille Cantarini, Karthick Vishwanathan, Pasi A. Jänne,...> ;Cancer Chemotherapy and Pharmacology. 2016 Feb 22
- 9 citationsAn open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin.Philip T. Leese, John M. Trang, Robert A. Blum, Eleanor de Groot> ;Clinical Pharmacology in Drug Development. 2015 Mar 1
- Join now to see all
Professional Memberships
- Member